Thrombophlebitis Leg

Phlogenzym

Placebo

Dr. Baumueller

Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance

Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance - Randomised Double-blind Study Phase III With Parallel Groups vs. Placebo According to the Guidelines of Good Clinical Practice (GCP)

Patients were asked to evaluate resting pain on day 0 (baseline) as well as day 7 on a 10-cm VAS (Visual Analogue Scale), with the left end (0 cm) indicating "no pain" and the right end (10 cm) "unbearable pain". The distance from the left end was recorded.

Number of responders (pain value smaller or equal to 1 cm on visual analogue scale for pain (VAS, eft end (0 cm) indicating "no pain" and the right end (10 cm) "unbearable pain") on day 14

Meyer's pressure points at the lateral side of the tibia and Krieger's pressure point in the popliteal space, 4-point rating scale ranging from 0 (no pain) to 3 (severe pain)

skin redness, hyperthermia, palpable/visible phlebitic cords, heaviness, tenseness

Sum score of all described symptoms (skin redness, hyperthermia, palpable/visible phlebitic cords, heaviness, tenseness)

Mucos Pharma GmbH & Co. KG

single dose of diclofenac 25 mg without pre-exposure to pineapple juice

single dose of diclofenac 25 mg with pre-exposure to pineapple juice

ananas erectifolius/protease

Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance

In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice

Najkompletnejšia databáza liečivých bylín podporovaná vedou